Home > Insider Trading > Filing (0001209191-18-034204)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659323	Iterum Therapeutics Plc	ITRM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1322927	Karl Brenton Ahrens	C/O Canaan Partners 285 Riverside Ave., Suite 250 Westport CT 06880		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2018-05-30	721,408	$0.00	721,408	No	4	C	Indirect	By Canaan X, L.P.
Ordinary Shares	Acquisiton	2018-05-30	275,446	$0.00	996,854	No	4	C	Indirect	By Canaan X, L.P.
Ordinary Shares	Acquisiton	2018-05-30	229,660	$0.00	1,226,514	No	4	C	Indirect	By Canaan X, L.P.
Ordinary Shares	Acquisiton	2018-05-30	506,656	$13.00	1,733,170	No	4	P	Indirect	By Canaan X, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Canaan X, L.P.
No	4	C	Indirect	By Canaan X, L.P.
No	4	C	Indirect	By Canaan X, L.P.
No	4	P	Indirect	By Canaan X, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Series A Preferred Shares	Disposition	2018-05-30	721,408	$0.00	721,408	$0.00
Ordinary Shares	Series B-1 Preferred Shares	Disposition	2018-05-30	275,446	$0.00	275,446	$0.00
Ordinary Shares	Series B-2 Preferred Shares	Disposition	2018-05-30	229,660	$0.00	229,660	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.